

PUBLICATIONS

Journal Articles:

1. Agarwal NK, Kim CH, Kunkalla K, Konno H, Tjendra Y, Kwon D, Blonska M, Kozloski GA, Moy VT, Verdun RE, Barber GN, Lossos IS, **Vega F**. Active IKK β Promotes the Stability of GLI1 Oncogene in Diffuse Large B-cell Lymphoma. *Blood* 2016 (In press)
2. Campuzano-Zuluaga G, Deutsch Y, Salzberg M, Gomez A, Vargas F, Elias R, Kwon D, Goodman M, Ikpatt OF, Chapman JR, Watts J, **Vega F**, Swords R. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better? *Am J Hematol* 2016 (In press)
3. Bueso-Ramos CE, Medeiros LJ, **Vega F**. Introduction to the 2013 workshop of the society for hematopathology/European association for hematopathology. *Am J Clin Pathol* 144:4-5; 2015
4. Campuzano-Zuluaga G, Ortiz D, Peng JH, Ikpatt OF, Fan YS, Barredo JC, **Vega F**, Chapman FR. Primary mediastinal large B-cell lymphoma with translocations involving BCL6 and MYC. *Am J Clin Pathol* 2015 (In press)
5. Samaniego F, Hagemester F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, **Vega F**, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B cell lymphomas. *Br J Haematol* 169:814-23; 2015.
6. Ruiz-Cordero R, Chapman J, **Vega F**. Synaptophysin is frequently expressed in megakaryocytes: a novel immunohistochemical finding of unknown significance. *Rev LatinoAmer Patol Clin* 62:76-80; 2015.
7. Chapman-Fredricks J, Gentles A, Sujoy V, **Vega F**, Dumar C, Blevins T, Bernal-Mizrachi L, Mosunjac M, Pimentel A, Zhu D, Lossos I. Gene Expression Analysis of Plasmablastic Lymphoma Identifies Down Regulation of B Cell Receptor Signaling and Additional Unique Transcriptional Programs. *Leukemia* 2015 (in press)
8. Blonska M, Agarwal N, **Vega F**. Shaping of the tumor microenvironment: stromal cells and vessels. *Semin Cancer Biol* 34:3-13; 2015.
9. Ruiz-Cordero, R, Lewis J, Blieden C, Campuzano-Zuluaga G, Hernandez J, Lossos IS, Ikpatt F, Chapman JR, **Vega F**. Unusual immunophenotypic variant of large B-cell lymphoma associated with HHV-8 and EBV in an HIV positive patient. *Hum Path: Case Reports* 2015 (in press).
10. Zhu D, Bhatt S, Lu V, Guo F, Veelken H, Hsu D, Liu F, Cubela S, Kunkalla K,

Vega F, Chapman-Fredricks J, and Lossos I. Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas express self polyreactive B cell receptors. *Leukemia* 29:1587-99; 2015

11. Blonska M, Zhu Y, Chuang HH, You JM, Kunkalla K, **Vega F**, Lin X. Jun-regulated genes promote interaction of diffuse large B cell lymphoma with the microenvironment. *Blood* 125:981-91; 2015

12. **Vega F**, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN. Hematolymphoid Neoplasms associated with rearrangements of *PDGFR-A*, *PDGFR-B* and *FGFR1*. *Am J Clin Pathol* 144:377-92; 2015.

13. Blieden C, Fan YS, Chapman JR, **Vega F**. De novo acute myeloid leukemia with monocytoid blasts and erythrophagocytosis. *Clin Case Rep* 2:333-5; 2014

14. Blieden C, Campuzano-Zuluaga G, Moul A, Chapman JR, Cioffi-Lavina, Ikpatt OF Byrne GE, **Vega F**. Anaphylactic Reaction to Platelet Transfusion as the Initial Symptom of an Undiagnosed Systemic Mastocytosis: A Case Report and Review of the Literature. *J Med Case Rep* 26;8:389; 2014

15. Blieden C, Medeiros LJ, **Vega F**. Acquired B-cell immunophenotype of follicular dendritic cells in a B-cell depleted lymph node after treatment with rituximab *Ann Hematol* 93:1947-8; 2014

16. Chapman-Fredricks J, Sandoval-Sus J, **Vega F**, Lossos IS. Progressive Leukemic Non-nodal Mantle Cell Lymphoma Associated with Deletions of TP53, ATM, and / or 13q14. *Ann Diagn Pathol* 18:214-9, 2014

17. Gera S, Dekmezian MS, Duvic M, Tschen J, **Vega F**, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement. *Am J Dermatopathol* 36:244-51; 2014.

18. Cho-Vega JH, **Vega F**, CD30-negative lymphomatoid papulosis type D in an elderly man. *Am J Dermatopathol* 36:190-2, 2014.

19. Leventaki V, Oki Y, Romaguera J, **Vega F**. Indolent Peripheral T-Cell Lymphoma Involving the Gastrointestinal Tract. *Human Pathol* 45:421-6, 2014.

20. Oki Y, Westin JR, **Vega F**, Chuang H, Fowler N, Neelapu S, Hagemester FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. *Br J Haematol* 163:611-20, 2013.

21. Merrit BY, Curry JL, Duvic M, **Vega F**, Sheehan AM, Curry CV. Pediatric subcutaneous panniculitis-like T-cell lymphoma with features of hemophagocytic syndrome. *Pediatr Blood Cancer* 60:1916-7, 2013.
22. Handal B, Entow R, Lara D, Bailey M, **Vega F**, Hu P, Lennon A. Investigating the expression of oncogenic and tumor suppressive microRNA in DLBCL. *J Assoc Genet Technol* 2013;39: 14-20
23. Sánchez-Espiridión B, Martín-Moreno AM, Montalbán C, Figueroa V, **Vega F**, Younes A, Medeiros LJ, Alvés FJ, Canales M, Estévez M, Menarguez J, Sabín P, Ruiz-Marcellán MC, Lopez A, Sánchez-Godoy P, Burgos F, Santonja C, López JL, Piris MA, Garcia JF. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. *Br J Haematol* 162:336-47, 2013.
24. Jain P, **Vega F**, Faderl S. “Cup-like” blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML). *Int J Hematol* 98:3; 2013.
25. Qu C, Liu Y, Kunkalla K, Sing RR, Blonska, M, Lin X, Agarwal NK, **Vega F**. Trimeric G protein-CARMA1 axis links smoothed, the hedgehog receptor transducer, to NF-KB activation in diffuse large B-cell lymphoma. *Blood* 121:4718-28, 2013.
26. Agarwal NK, Qu C, Kunkalla K, Liu Y, **Vega F**. Transcriptional regulation of Serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. *J Biol Chem* 288:15390-401, 2013
27. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandaythapani V, Luong A, **Vega F**, Fowler N, Dong C, Davis E, Neelapu SS. Cross talk between follicular helper T cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. *J Immunol* 190:6681-93, 2013.
28. **Vega F**. Time to look for CD30 expression in diffuse large B cell lymphomas, along the way to immunotherapy. *Leuk Lymphoma* 54:2341-2; 2013.
29. Kunkalla K, Liu Y, Changju Q, Leventaki V, Agarwal NK, Singh R, **Vega F**. Functional Inhibition of BCL2 is needed to Increase the Susceptibility to Apoptosis to SMO Inhibitors in Diffuse Large B-Cell Lymphoma of Germinal Center Subtype. *Ann Hematol* 92:777-87, 2013.
30. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, Konoplev S, Bueso-Ramos CE, **Vega F**, Medeiros LJ, Yin CC. Extranodal NK/T cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. *Am J Surg Pathol* 37:14-23, 2013.
31. Kanagal-Shamanna R, Medeiros LJ, Lu G, Wang SA, Manning JT, Lin P, Penn GM, Young KH, You MJ, **Vega F**, Bassett R, Miranda RN. High-grade B cell lymphoma unclassifiable, with blastoid feature: an unusual morphological subgroup associated

frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. *Histopathology* 61:945-54, 2012.

32. Greaves WO, Xiao L, Sanchez-Espiridion B, Kunkalla K, Dave KS, Liang CS, Singh RR, Younes A, Medeiros LJ, **Vega F**. Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. *J Hematol Oncol* 5:47, 2012. PMID:3470996

33. Ramirez E, Singh RR, Kunkalla K, Liu Y, Cain C, Multani AS, Lennon PA, Jackacky J, Dawud S, Gu J, Yang S, Hu PC, **Vega F**. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma. *Leuk Res* 36:1267-73, 2012.

34. Buglio D, Palakurthi S, Byth K, **Vega F**, Toader D, Saeh J, Neelapu SS, Younes A. Essential role of TAK1 in regulating mantle cell lymphoma survival. *Blood* 120:347-55, 2012

35. Li C, Thompson MA, Tamayo AT, Zuo Z, Lee J, **Vega F**, Ford RJ, Pham LV. Over-expression of thioredoxin-1 mediates growth, survival, and chemoresistance and is a drugable target in diffuse large B-cell lymphoma. *Oncotarget* 3:314-26, 2012. PMID:3359887

36. Kim K, Leventaki L, Bhajjee F, Jackson CC, Medeiros LJ, **Vega F**. Extracavitary/Solid Variant of Primary Effusion Lymphoma. *Ann Diagn Pathol* 16:441-6, 2012.

37. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Medeiros LJ, **Vega F**, Younes A, Piris MA, Garcia JF. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma. *Haematologica* 97:1080-4, 2012. PMID:3396681

38. Meadows SA, **Vega F**, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ. PI3K δ inhibitor, GS-1101(CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. *Blood* 119:1897-900, 2012

39. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, **Vega F**. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. *Mod Pathol* 25:231-6, 2012.

40. Ok CH, Singh RR, **Vega F**. Aberrant activation of hedgehog signaling pathway in hematological neoplasms. *Am J Pathol* 180:2-11, 2012. PMC 3338341

41. Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, **Vega F**, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ. Expression of serine 194-phosphorylated Fas-

associated death domain protein correlates with proliferation in B-cell non-Hodgkin-type lymphomas. *Hum Pathol* 42:1117-24, 2011.

42. Cho-Vega JH, **Vega F**. CD4 CD8 Double-Negative Early Stage Mycosis Fungoides Associated with Primary Cutaneous Follicular Center Lymphoma. *J Am Acad Dermatol* 65:884-6, 2011.

43. Drakos E, Singh RR, Rassidakis GZ, Schlette EJ, Li J, Claret FX, Ford RJ, **Vega F**, Medeiros LJ. Activation of p53 pathway by MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma. *Leukemia* 25:856-67, 2011.

44. Singh R, Kunkalla K, Qu C, Schlette E, Neelapu S, Samaniego F, **Vega F**. ABCG2 is a Direct Transcriptional Target of Hedgehog Signaling and Involved in Stroma-Induced Drug Tolerance in Diffuse Large B-Cell Lymphoma. *Oncogene* 30:4874-86, 2011. PMID:3165099

45. Curry LJ, Prieto VG, Jones DM, **Vega F**, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sezary syndrome. *J Cutan Pathol* 38:295-7, 2011.

46. Greaves WO, Kim JE, Singh RR, Drakos E, Kunkalla K, Sánchez-Espiridión B, Garcia JF, Medeiros LJ, **Vega F**. Glioma associated oncogene homologue 3 (GLI3), a Hedgehog transcription factor, is highly expressed in Hodgkin and Reed-Sternberg cells of Classical Hodgkin lymphoma. *Hum Pathol* 42:1643-52, 2011. PMID:3165071

47. Hsu C, **Vega F**, Grimes LM, Hunt KK. Follicular dendritic cell sarcoma and associated myasthenia gravis: true, true, related? *J Clin Oncol* 29:369-71, 2011.

48. Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, **Vega F**, Medeiros LJ, Ford RJ. Constitutive BR3 receptor signaling in diffuse large B-cell lymphomas stabilizes NK- κ B-inducing kinase, while activating both canonical and alternative NF- κ B pathways. *Blood* 117:200-10, 2011. PMID: 3037744.

49. Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, **Vega F**, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV. Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. *Am J Clin Path* 135:686-96, 2011.

50. Vishwamitra D, Shi P, Wilson D, Manshoury R, **Vega F**, Schlette EJ, Amin HM. Expression and effects of inhibition of IGF-IR tyrosine kinase in mantle cell lymphoma. *Haematologica* 96:871-90, 2011. PMID:3105649.

51. **Vega F**, Medeiros LJ. V(D)J recombination and staggered DNA breaks: guilty again. *Blood* 115:2121-2, 2010.

52. Wang SA, Jabbark, Lu G, Chen SS, Galili N, **Vega F**, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. *Leukemia* 24:740-7, 2010.
53. **Vega F**, Davuluri Y, Cho-Vega JH, Ma S, Wang RU, Multani AS, Drakos I, Pham L, Shen L, Ambrus J, Medeiros LJ, Ford R. Side population contains cells with "tumor-initiating cell" features responsible for lymphoma maintenance and systemic dissemination. *J Cell Mol Med* 14:1532-45, 2010.
54. Singh RR, Kim JE, Davuluri Y, Drakos-E, Cho-Vega JH, Amin H, **Vega F**. Hedgehog-signaling pathway contributes to tumor cell survival and proliferation in diffuse large B-cell lymphoma. *Leukemia* 24:1025-36, 2010.
55. Cho-Vega JH, Tschen J, Duvic M, **Vega F**. Early stage mycosis fungoides variants: Case based review. *Ann Diagn Pathol* 14:369-85, 2010.
56. Khokhar FA, Payne WD, Talwalkar SS, Jorgensen J, Bueso-Ramos C, Medeiros LJ, **Vega F**. Angioimmunoblastic T-Cell Lymphoma in Bone Marrow: A Morphologic and Immunophenotypic Study. *Hum Pathol* 41:79-87, 2010.
57. Singh RR, Cho-Vega JH, Davuluri y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, **Vega F**. Sonic Hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. *Cancer Res* 69:2550-8, 2009.
58. Drakos E, Rassidakis RZ, Leventaki V, Cotta C, **Vega F**, Medeiros LJ. Nodular Lymphocyte predominant Hodgkin lymphoma with clusters of L&H-like cells, acute inflammation, and fibrosis: a syncytial variant. *Am J Surg Pathol* 33:1725-31, 2009.
59. Falchook G, **Vega F**, Dang N, Samaniego F, Rofriguez M, Champlin R, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. *Ann Oncol* 20:1080-1085, 2009.
60. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Fayad L, Medeiros LJ, **Vega F**. Hedgehog (SHH)-signaling proteins and ATP binding cassette (ABC) are aberrantly expressed in diffuse large B-cell lymphoma. *Mod Pathol* 10:1312-20, 2009.
61. Jain N, Hubbard J, **Vega F**, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous Remission of Acute Myeloid Leukemia: Report of Three Cases and Review of the Literature. *Clin Leuk* 2:64-67, 2008.
62. **Vega F**, Cho-Vega JH, Lennon PA, Luthra MG, Bailey J, Breeden M, Jones D, Medeiros LJ, Luthra R. Splenic Marginal Zone Lymphomas are characterized by loss of Interstitial Regions of Chromosome 7q,7q31.32 and 7q36.2, that include protection of Telomere 1 (POT1) and Sonic Hedgehog (SHH) Genes. *Br J Haematol* 142:216-226, 2008.

63. Huh Yang, I-Chun Lin K, **Vega F**, Schlette E, Yin C, Keating M, Luthra R, Medeiros LJ and Abruzzo L. MYC translocation in chronic lymphocytic leukemia is associated with increased prolymphocytes and a poor prognosis. *Br J Haematol* 142:36-44, 2008.
64. Cho-Vega JH, Medeiros LJ, Prieto VG, **Vega F**. Leukemia Cutis. *Am J Clin Pathol* 129:130-42, 2008.
65. Cho-Vega JH, **Vega F**, Medeiros LJ. An Attractive Therapeutic Target, mTOR Pathway, for an Effective Combinatorial Cancer Therapy in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. *Adv Anat Pathol* 15:105-12, 2008.
66. Quintas-Cardama A, Tong W, Manshoury T, **Vega F**, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human nup214-abl-positive T-cell malignancies. *Leukemia* 22:1117-1124, 2008.
67. **Vega F**, Medeiros LJ, Davuluri R, Alkan S, Abruzzo LV. t(8;13)-positive bilineal lymphomas:report of six cases. *Am J Surg Pathol* 32:14-20, 2008.
68. **Vega F**, Medeiros LJ, Gaulard P. Hepatosplenic and other gamma delta T-cell Lymphomas. *Am J Clin Pathol* 127:869-80, 2007.
69. Cho-Vega JH, **Vega F**, Schwartz MR, Prieto VG. Expression of dicarbonyl/L-xylulose reductase (DCXR) in human skin and melanocytic lesions:morphological studies supporting cell adhesion function of DCXR. *J Cutan Pathol* 34:535-542, 2007.
70. **Vega F**, Coombes KR, Thomazy VA, Patel K, Lang W, Jones D. Tissue-Specific Function of Lymph Node Fibroblastic Reticulum Cells. *Pathobiology* 73:71-81, 2006.
71. **Vega F**, Padula A, Valbuena JR, Stancu M, Jones D, Medeiros LJ. Systemic lymphomas involving the pleura. A Clinicopathologic study of 34 cases diagnosed by pleural biopsy. *Arch Pathol Lab Med* 130:1497-1502, 2006.
72. Cho-Vega JH, **Vega F**, Rassidakis G, Medeiros LJ. Primary Cutaneous Marginal Zone B-Cell Lymphoma. *Am J Clin Pathol* 125:S38-S49, 2006.
73. **Vega F**, Chang CC, Schwartz MR, Verm R, Preti HA, Etwon A, Younes M, Jaffe ES. Atypical NK-cell proliferation of the gastrointestinal tract in a patient with antigliadin antibodies but not celiac disease. *Am J Surg Pathol* 4:539-544, 2006.
74. **Vega F**, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mTOR Signaling Pathway Contributes to Tumor Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma. *Cancer Res* 66:6589-97, 2006.

75. Lin P, Jones D, Medeiros LJ, Chen W, **Vega F**, Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. *Am J Clin Pathol* 126:1-4, 2006.
76. **Vega F**, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch C, Vilchez RA, McGregor DK, Jorgensen JL. Plasmablastic lymphomas and plasmablastic plasma cell myeloma have nearly identical immunophenotypic profiles. *Mod Pathol* 18:806-815, 2005.
77. **Vega F**, Lin P, Medeiros LJ. Extranodal lymphomas of the head and neck. *Ann of Diagn Pathol* 9:340-350, 2005.
78. Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurgers K, Remache YK, **Vega F**, Goy AH, Gilles F, Medeiros LJ. Suppressor of cytokine signaling 3 expression in anaplastic cell lymphoma. *Leukemia* 18:1872-1878, 2004.
79. Thomazy VA, **Vega F**, Medeiros LJ, Davis PJ, Jones D. Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes: transglutaminase reveals coordinate regulation. *Am J Pathol* 163:165-174, 2003. PMID:1868169
80. **Vega F**, Medeiros LJ. Chromosomal translocations involved in non-Hodgkin lymphomas. *Arch Pathol Lab Med* 127:1148-1160, 2003.
81. **Vega F**, Medeiros LJ, Lang WH, Mansoor A, Bueso-Ramos C, Jones D. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumors. *Br J Haematol* 117:569-576, 2002.
82. Sanchez-Vega B, **Vega F**, Hai S, Medeiros LJ, Luthra R. Real-time t(14;18) PCR assay combined with high resolution PCR fragment analysis: A novel approach to monitor disease/tumor burden in follicular lymphoma patients. *Mod Pathol* 15:441-453, 2002.
83. **Vega F**, Medeiros LJ, Luthra R. Taqman PCR in the detection and of chromosomal translocations in follicular lymphoma, mantle cell lymphoma and chronic myeloid leukemia. *Internet J Pathol* 2(1), 2002.
84. **Vega F**, Orduz R, Medeiros LJ. Roles of common chromosomal translocations in non-Hodgkin's lymphomas. *Pathology* 34:397-409, 2002.
85. Abruzzo LV, Rosales CM, Medeiros LJ, **Vega F**, Luthra R, Manning JT, Keating MJ, Jones D. Related Articles Epstein-Barr virus positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. *Am J Surg Pathol* 26:630-636, 2002.

86. Sanchez-Vega B, **Vega F**, Medeiros LJ, Lee MS, Luthra R. Quantification of BCL-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis. *J Mol Diagn* 4:223-229, 2002. PMID:1907359
87. Onciu M, Lai R, **Vega F**, Bueso-Ramos C, Medeiros LJ. Precursor T-cell acute lymphoblastic leukemia in adults. *Am J Clin Pathol* 117:252-258, 2002.
88. Stancu M, Jones D, **Vega F**, Medeiros LJ. Peripheral T-cell lymphoma arising in the liver. *Am J Clin Pathol* 118:574-581, 2002.
89. Sen F, **Vega F**, Medeiros LJ. Molecular genetic methods in the diagnosis of hematologic neoplasms. *Semin Diagn Pathol* 19:72-93, 2002.
90. **Vega F**, Luthra R, Medeiros LJ, Dunmire V, Lee SJ, Duvic M, Jones D. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. *Blood* 100:3369-3373, 2002.
91. Jones D, **Vega F**, Sarris AH, Medeiros LJ. A CD4 and CD8 "double-negative" immunophenotype in cutaneous T-cell lymphoma is predictive of an aggressive clinical course. *Am J Surg Pathol* 26:225-231, 2002.
92. Calvo M, Firvida JL, **Vega F**, Salgado M, Garcia Mata J, Ruben M, Barreiro A. Wilms tumor in the adult. *Arch Esp Urol* 54:370-374, 2001.
93. **Vega F**, Medeiros LJ, Abruzzo LV. Primary paratesticular lymphoma: a report of two cases and literature review. *Arch Patol Lab Med* 125:428-432, 2001.
94. **Vega F**, Medeiros LJ. Marginal zone B-cell lymphoma of extranodal MALT-type. Molecular genetics provides new insights into pathogenesis. *Adv Anat Pathol* 8:313-326, 2001.
95. **Vega F**, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Luthra R, Abruzzo LV. Hepatosplenic T-cell lymphoma in bone marrow: An intra-sinusoidal neoplasm with blastic cytologic features. *Am J Clin Pathol* 116:410-419, 2001.
96. **Vega F**, Medeiros LJ. Chromosomal translocations in Non-Hodgkin's lymphomas (Part II). *Patologia* 34:353-366, 2001.
97. **Vega F**, Medeiros LJ. Chromosomal translocations in Non-Hodgkin's lymphomas (Part I). *Patologia* 34:277-286, 2001.
98. **Vega F**, Medeiros LJ, Jones D, Abruzzo LV, Lai R, Manning J, Dunmire V, Luthra R. A novel 4-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. *Am J Clin Pathol* 116:17-24, 2001.

99. Olivieri DN **Vega F**. Image prototype similarity matching for lymph node hemopathology. Proceedings - International Conference on Pattern Recognition 2000;15(2):279-282.
100. Panizo A, Sola I, **Vega F**, de Alava E, Lozano MD, Idoate MA, Pardo-Mindan FJ. Predicting metastatic risk of gastrointestinal stromal tumors: role of cell proliferation and cell cycle regulatory proteins. *Int J Surg Pathol* 8:133-144, 2000.
101. Rodriguez-Gomez M, Fernandez-Sueiro JL, Willisch A, Fernandez-Dominguez L, Lopez-Barros G, **Vega F**. Multifocal dactylitis as the sole clinical expression of sarcoidosis. *J Rheumatol* 27:245-247, 2000.
102. **Vega F**, Diaz MS. Extramedullary hematopoiesis in polyposis. *Gastrointest Endosc* 51:330-331, 2000.
103. **Vega F**, Panizo A, Diez, Pardo-Mindan FJ. Susceptibility to apoptosis of arterioles and capillaries in adult spontaneously hypertensive rats. *Am J Hypertens* 12:815-820, 1999.
104. **Vega F**, Lozano MD, Alcade J, Pardo-Mindan FJ. Role of the immunohistochemical and molecular biology in necrotic lymph node. *Virchows Arch* 434:245-248, 1999.
105. Pastrana J, Conchillo MA, **Vega F**, Beloqui O. Granulomatosis linfomatoide pulmonar asociada a SIDA. Descripción de un caso y revisión de la literatura. *An Med Interna* 15:487-489, 1998.
106. Panizo A, **Vega F**. Revisión de la técnica del TUNEL. *Patología* 30:243-245, 1997.
107. **Vega F**, Errasti F, Pardo-Mindan FJ. Renal transplantation from a donor with a Nail-Patella syndrome. *Nephrol Dial Transp* 12:1742-1744, 1997.
108. Arriagada C, Leyes, M, Valenti JR, **Vega F**. Papel de la artroscopia en la condrocalcinosis. *Cuadern Artroscopia* 4:21-25, 1997.
109. Panizo A, **Vega F**. Glosario de biología molecular. *Patología* 30:259-260, 1997.
110. Perez-Requena J, **Vega F**, Guezmez Domingo A, Ruiz ML, Paloma Gonzalez MJ, Diaz I. Gliomatosis peritoneal: presentación de dos casos asociados a gliomatosis ganglionar y ovarica y elevación de las concentraciones de alfa-fetoproteína. *Patología* 30:150-153, 1997.
111. Idoate MA, **Vega F**. Diagnóstico de las enfermedades neurometabólicas y neurodegenerativas mediante biopsia cutánea. *Rev Neurol* 25:S269-S280, 1997.

112. Diez J, Panizo A, Hernandez M, **Vega F**, Sola I, Fortuno MA, Pardo J. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. *Hypertension* 30:1029-1034, 1997.
113. Arias M, Abreu JA, Iglesias A, Longo J, Lecumberri F, **Vega F**. Primary amyloidosis presenting as renal infarction. *Eur-Radiol* 6:346-8, 1996.
114. Garcia-Rayo S, Gurrpide A, **Vega F**, Brugarolas A. Regresion tumoral espontanea en un paciente con mieloma multiple. Comunicacion de un caso adicional. *Rev Med Univ Navarra* 40:27-30, 1996.
115. **Vega F**, Sierrasesumaga L, Panizo A, Diaz L, Foncillas J. Metastasis Pulmonares de Osteosarcoma: Factores pronosticos. *Patologia* 29:325-331, 1996.
116. **Vega F**, Diaz L, Castro I, Panizo A, Sierrasesumaga L, Pardo-Mindan FJ. Metastasis ganglionares de osteosarcomas. *Rev Med Univ Navarra* 40:27-30, 1996.
117. **Vega F**. Pseudomixoma Peritonei. *Rev Med Univ Navarra* 2:64, 1996.
118. **Vega F**. Adenocarcinoma de Sigma. *Rev Med Univ Navarra* 40:190, 1996.
119. **Vega F**, Pardo-Mindan FJ. Carcinoma Gastrico de Celulas en Anillo de Sello. *Rev Med Univ Navarra* 39:47; 1995.
120. **Vega F**, Pardo-Mindan FJ. Carcinoma Difuso Gastrico. *Rev Med Univ Navarra* 39:84, 1995.
121. Gimeno Ballester J, Ruza-Paz Curbera E, Crespo Cuadrado E, Azcona San Julian C, **Vega F**, Sierrasesumaga L. Actualizacion de la Hepatitis C. A proposito de un caso. *Bol S Vasco-Nav Ped* 89:79-85; 1995.
122. **Vega F**, Pardo-Mindan FJ. Quiste Hidatidico Hepatico. *Cir Iber Americana* 3:62, 1994.
123. **Vega F**, Pardo-Mindan FJ. Colecistitis Cronica Esclerosante. *Rev Med Univ Navarra* 39:30, 1994.
124. **Vega F**, Pardo-Mindan FJ. Carcinoma Ductal Infiltrante de Mama. *Cir Iber Americana* 3:127, 1994.

Letters to the Editor

1. **Vega F**. Uterine Rupture. *N Eng J Med* 339:268-269, 1998.
2. Lamela J, **Vega F**, Blanco J. Airway obstruction in chronic obstructive pulmonary disease. *N Eng J Med* 351:1459-1461, 2004.

3. Lamela J, **Vega F**. Immunologic aspects of chronic obstructive pulmonary disease. N Eng J Med 361:1024, 2009.

Books and Monographs published:

1. Book chapters for the forth series of the Tumors of the Lymph node and Spleen lymphoma; Atlas of Tumor Pathology of the AFIP (Armed Forces Institute of Pathology) Scheduled for 2016.
2. Blieden C, Agarwal NK, **Vega F**. Microenvironment abnormalities and cytokine network deregulation in lymphoma genesis and progression. Future Science Group. UK, London, 2015: 35-50.
3. **Vega F**. Lymphomas involving the lung and pleura. In: Annikka Weissferdt & Cesar A. Moran, editors. Diagnostic Pathology of Pleuropulmonary Neoplasia. Springer: New York, 319-347, 2013.
4. Leventaki V, **Vega F**. Molecular Diagnostics of Lymphoid Malignancies. In: Cheng, Zhang and Eble editors. Molecular Genetic Pathology. 2nd edition Springer. 887-928, 2013.
5. Cho-Vega JH, **Vega F**. Essentials in Cancer Cytogenetics. In: Garcia-Foncillas, J editor. Molecular Biology in cancer, an approach to new therapies. Barcelona: Prouse Science: Barcelona, 1-27, 2009.
6. **Vega F**, Jones D. Molecular Diagnostics of Lymphoid Malignancies. In: Essentials of Molecular/Genetic Pathology. Humana Press, 655-674, 2008.
7. **Vega F**, Toledo G. Alteraciones Anatomo-Patologicas de las Vias Aereas en el Asma bronquial. In: Asma Vision Actual. Aula Medica Ediciones, 33-54, 2001.
8. Idoate M, **Vega F**. Mecanismos Implicados en la Afectacion Cutanea por la Enfermedad de Injerto contra Huesped. In: Fisiopatologia de las Enfermedades Cutaneas II. Schering Plough, 281-303, 1999.
9. Cervera J, **Vega F**, Garcia-Tapia R. Estructura Histologica de las Cuerda Vocal. In: Diagnostico y Tratamiento de la Voz. Garsi, 48-53, 1996.
10. Cervera J, **Vega F**, Garcia-Tapia R. Lesiones Benignas de las Cuerdas Vocales. In: Diagnostico y Tratamiento de los Transtornos de la Voz. Garsi, 223-240, 1996.
11. **Vega F**, Panizo A, Pardo-Mindan FJ. Caracteristicas Biologicas de los Tumores. In: Enfermeria Oncologica. Ediciones Eunsa, 15-45, 1995.

Author of the following chapters for the Book Diagnostic Pathology Series Amirsys:
-Lymphomas and reactive diseases involving lymph nodes, spleen with extranodal lymphomas. In: LJ Medeiros editor. Amirsys publishing. Salt Lake City, Utah.

Syphilitic Lymphadenitis 2:54-55,
Inflammatory Pseudotumor Involving Lymph Node 3:2-7,
Diffuse Large B-cell Lymphoma, NOS, centroblastic 6:52-55,
Diffuse Large B-cell Lymphoma, NOS, Immunoblastic 6:56-61,
T-cell/Histiocyte Rich Large B-cell Lymphoma 6:62-65,
Plasmablastic Lymphoma 7:68-77,
Primary effusion lymphoma (PEL) and solid variant of PEL 7:78-83,
Primary Mediastinal (Thymic) Large B-cell Lymphoma 7:34-43,
Lymphomatoid Granulomatosis 7:86-95,
Intravascular Large B-cell Lymphoma 7:96-101,
B-cell Lymphomas, unclassifiable, with features intermediate between Diffuse Large B cell Lymphoma and Classical Hodgkin Lymphoma 8:8-17,
Anaplastic Large Cell Lymphoma, ALK+ 9:30-35,
Anaplastic Large Cell Lymphoma, ALK-, 9:36-39,
Classical Hodgkin Lymphoma in Spleen, 14:82-85
Hepatosplenic T-cell Lymphoma, 14:86-95.

-Author of additional chapters for the Diagnostic Pathology Series for the following books:

Neoplastic Dermatopathology. In: D. Cassarino editor. Amirsys publishing, 2013
Intravascular large B cell lymphoma involving the skin, I12:28-31.

Familial Cancer Syndromes. In: V. Nose editor. Amirsys publishing, 2014
Diffuse large B cell lymphoma, II-2:8-13.

Diagnostic Pathology Spleen. In A. Auerbach editor. Amirsys publishing, 2014
Hepatosplenic T-cell lymphoma, 3:208-215.

Manuals, Teaching Aids

Pardo-Mindan FJ, Sola I, Idoate M, de Alva E, Lozano MD, Panozo A, **Vega F**, Diaz L, Fernandez J. CD-ROM INTERPAT Interactive Teaching of Anatomic Pathology by Computer, 1999. Pamplona (Navarra, Spain).